Back

Nonutility of procalcitonin for diagnosing bacterial pneumonia in COVID-19

Cohen, A. J.; Glick, L. R.; Lee, S.; Kunitomo, Y.; Tsang, D. A.; Pitafi, S.; Valda Toro, P.; Zhang, E.; Datta, R.; Dela Cruz, C. S.; Gautam, S.

2022-04-05 respiratory medicine
10.1101/2022.03.29.22272960 medRxiv
Show abstract

Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection. To do so, we identified 185 patients with severe COVID-19 who underwent lower respiratory culture; 85 had superinfection. Receiver operating characteristic curve analysis showed that procalcitonin at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). We conclude that static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.